» Articles » PMID: 31162883

Keeping Heart Homeostasis in Check Through the Balance of Iron Metabolism

Overview
Specialty Physiology
Date 2019 Jun 5
PMID 31162883
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Highly active cardiomyocytes need iron for their metabolic activity. In physiological conditions, iron turnover is a delicate process which is dependent on global iron supply and local autonomous regulatory mechanisms. Though less is known about the autonomous regulatory mechanisms, data suggest that these mechanisms can preserve cellular iron turnover even in the presence of systemic iron disturbance. Therefore, activity of local iron protein machinery and its relationship with global iron metabolism is important to understand cardiac iron metabolism in physiological conditions and in cardiac disease. Our knowledge in this respect has helped in designing therapeutic strategies for different cardiac diseases. This review is a synthesis of our current knowledge concerning the regulation of cardiac iron metabolism. In addition, different models of cardiac iron dysmetabolism will be discussed through the examples of heart failure (cardiomyocyte iron deficiency), myocardial infarction (acute changes in cardiac iron turnover), doxorubicin-induced cardiotoxicity (cardiomyocyte iron overload in mitochondria), thalassaemia (cardiomyocyte cytosolic and mitochondrial iron overload) and Friedreich ataxia (asymmetric cytosolic/mitochondrial cardiac iron dysmetabolism). Finally, future perspectives will be discussed in order to resolve actual gaps in knowledge, which should be helpful in finding new treatment possibilities in different cardiac diseases.

Citing Articles

Cardiac injury caused by iron overload in thalassemia.

Fu C, Yang X Front Pediatr. 2025; 13:1514722.

PMID: 39931654 PMC: 11808023. DOI: 10.3389/fped.2025.1514722.


Dexmedetomidine preconditioning attenuates ferroptosis in myocardial ischemia-reperfusion injury via α2 adrenergic receptor activation.

Wang M, Ren Z, Sun X, Li Y, Chen Z Heliyon. 2024; 10(21):e39697.

PMID: 39524900 PMC: 11544042. DOI: 10.1016/j.heliyon.2024.e39697.


Cardiomyocyte-specific overexpression of FPN1 diminishes cardiac hypertrophy induced by chronic intermittent hypoxia.

Song J, Xu S, Chen Q, Gou Y, Zhao C, Jia C J Cell Mol Med. 2024; 28(14):e18543.

PMID: 39054575 PMC: 11272608. DOI: 10.1111/jcmm.18543.


Involvement of Ferroptosis Induction and Oxidative Phosphorylation Inhibition in the Anticancer-Drug-Induced Myocardial Injury: Ameliorative Role of Pterostilbene.

Fujii K, Fujiwara-Tani R, Nukaga S, Ohmori H, Luo Y, Nishida R Int J Mol Sci. 2024; 25(5).

PMID: 38474261 PMC: 10931614. DOI: 10.3390/ijms25053015.


Assessment of the Impact of Carvedilol Administered Together with Dexrazoxan and Doxorubicin on Liver Structure and Function, Iron Metabolism, and Myocardial Redox System in Rats.

Szponar J, Gorska A, Ostrowska-Lesko M, Korga-Plewko A, Tchorz M, Ciechanski E Int J Mol Sci. 2024; 25(4).

PMID: 38396896 PMC: 10889540. DOI: 10.3390/ijms25042219.